Skip to main content
SpringerLink
Log in

Tumour Necrosis Factor-α Antagonists in the Management of Rheumatoid Arthritis in the Elderly

A Review of Their Efficacy and Safety

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease that frequently affects people aged ≥65 years, causing significant impairment with pain and functional disability. Elderly RA patients have specific problems, including co-morbid diseases, numerous concomitant medications, greater number of damaged joints as a result of longer disease duration and often a more severe disease presentation in elderly-onset RA. These factors, together with an age-related decline in the immune defence mechanisms, make elderly patients more vulnerable.

The new era of biologic medications has made intensive treatment of RA patients possible. Anti-tumour necrosis factor-α (anti-TNFα) agents can cause a dramatic improvement in disease activity and functional capacity, making complete remission of RA a possible target. TNFα has been shown to play an important role in both the healthy aging process and age-related diseases such as RA. Targeting this cytokine in elderly patients is therefore reasonable. However, it is not clear whether treatment effects can be reached to the same extent in both elderly and younger patients and whether anti-TNFα treatment specifically increases the risk of certain adverse events in elderly RA patients.

This review discusses the currently available evidence relating to the efficacy and safety of anti-TNFα medication in RA patients aged ≥65 years treated in clinical trials and observational studies. Despite a slightly less robust effect in elderly patients, anti-TNFα treatment has a similar long-term efficacy in patients aged ≥65 years and patients aged <65 years. The majority of the study results showed that anti-TNFα treatment does not elevate the risk of infections beyond the risk found in age-matched controls. When a moderate increase in risk was found, this occurred equally in elderly and younger patients. Furthermore, whereas anti-TNFα agents were found to be relatively safe in the treatment of elderly RA patients, treatment with corticosteroids significantly elevated the risk of serious infections. Corticosteroids are frequently used in elderly patients, but the evidence suggests that preference should increasingly be given to anti-TNFα agents, for which the expected benefits will mostly outweigh the modestly increased risks of associated adverse events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Table III

Similar content being viewed by others

References

  1. Kaipiainen-Seppanen O, Aho K, Isomaki H, et al. Shift in the incidence of rheumatoid arthritis toward elderly patients in Finland during 1975–1990. Clin Exp Rheumatol 1996; 14(5): 537–42

    PubMed  CAS  Google Scholar 

  2. Symmons DPM. Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res Clin Rheumatol 2002; 16(5): 707–22

    Article  PubMed  Google Scholar 

  3. Laiho K, Tuomilehto J, Tilvis R. Prevalence of rheumatoid arthritis and musculoskeletal diseases in the elderly population. Rheumatol Int 2001; 20(3): 85–7

    Article  PubMed  CAS  Google Scholar 

  4. Bergstrom G, Bjelle A, Sundh V, et al. Joint disorders at ages 70, 75 and 79 years: cross-sectional comparison. Br J Rheumatol 1986; 25(4): 333–41

    Article  PubMed  CAS  Google Scholar 

  5. Rasch EK, Hirsch R, Paulose-Ram R, et al. Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum 2003; 48(4): 917–26

    Article  PubMed  Google Scholar 

  6. Papadopoulos IA, Katsimbri P, Alamanos Y, et al. Early rheumatoid arthritis patients: relationship of age. Rheumatol Int 2003; 23(2): 70–4

    PubMed  Google Scholar 

  7. Linos A, Worthington JW, Ofallon WM, et al. Epidemiology of rheumatoid arthritis in Rochester, Minnesota: study of incidence, prevalence, and mortality. Am J Epidemiol 1980; 111(1): 87–98

    PubMed  CAS  Google Scholar 

  8. Weyand CM, Fulbright JW, Goronzy JJ. Immunosenescence epidemiology and rheumatoid arthritis. Exp Gerontol 2003; 38(8): 833–41

    Article  PubMed  CAS  Google Scholar 

  9. Makinodan T, Kay MMB. Age influence on the immune system. Adv Immunol 1980; 29: 287–330

    Article  PubMed  CAS  Google Scholar 

  10. Fleischmann R, Iqbal I. Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. Drugs Aging 2007; 24(3): 239–54

    Article  PubMed  CAS  Google Scholar 

  11. Wolfe F, Michaud K, Dewitt EM. Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues. Ann Rheum Dis 2004; 63Suppl. 2: ii13–7

    Article  PubMed  CAS  Google Scholar 

  12. European Medicines Agency. European public assessment report [online]. Available from URL: http://www.emea.europa.eu/htms/human/epar/eparintro.htm [Accessed 2009 May 21]

  13. Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003; 30(12): 2563–71

    PubMed  CAS  Google Scholar 

  14. Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004; 50(4): 1051–65

    Article  PubMed  CAS  Google Scholar 

  15. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340(4): 253–9

    Article  PubMed  CAS  Google Scholar 

  16. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48(1): 35–45

    Article  PubMed  CAS  Google Scholar 

  17. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343(22): 1586–93

    Article  PubMed  CAS  Google Scholar 

  18. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46(6): 1443–50

    Article  PubMed  CAS  Google Scholar 

  19. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50(11): 3432–43

    Article  PubMed  CAS  Google Scholar 

  20. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363(9410): 675–81

    Article  PubMed  CAS  Google Scholar 

  21. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radio-graphic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50(5): 1400–11

    Article  PubMed  CAS  Google Scholar 

  22. van Riel PL, Freundlich B, MacPeek D, et al. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial. Ann Rheum Dis 2008; 67(8): 1104–10

    Article  PubMed  Google Scholar 

  23. Kievit W, Fransen J, Oerlemans AJM, et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomized controlled trials and clinical practice. Ann Rheum Dis 2007; 66(11): 1473–8

    Article  PubMed  CAS  Google Scholar 

  24. Zink A, Strangfeld A, Schneider M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 2006; 54(11): 3399–407

    Article  PubMed  CAS  Google Scholar 

  25. Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 2005; 34 (5 Suppl. 1): 19–22

    Article  PubMed  CAS  Google Scholar 

  26. Mpofu S, Fatima F, Moots RJ. Anti-TNF-alpha therapies: they are all the same (aren’t they?). Rheumatology (Oxford) 2005; 44(3): 271–3

    Article  CAS  Google Scholar 

  27. Schwartzman S, Fleischmann R, Morgan Jr GJ. Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis? Arthritis Res Ther 2004; 6Suppl. 2: S3–11

    Article  PubMed  CAS  Google Scholar 

  28. Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64(10): 1414–20

    Article  PubMed  CAS  Google Scholar 

  29. Curtis JR, Patkar N, Xie AY, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007; 56(4): 1125–33

    Article  PubMed  CAS  Google Scholar 

  30. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving antitumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54(8): 2368–76

    Article  PubMed  CAS  Google Scholar 

  31. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009 Jul; 68(7): 1136–45

    Article  PubMed  CAS  Google Scholar 

  32. Dixon WG, Symmons DPM, Lunt M, et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007; 56(9): 2896–904

    Article  PubMed  CAS  Google Scholar 

  33. Askling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007; 66(10): 1339–44

    Article  PubMed  Google Scholar 

  34. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 2005; 44(6): 714–20

    Article  PubMed  CAS  Google Scholar 

  35. Mohan AK, Cote TR, Block JA, et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004; 39(3): 295–9

    Article  PubMed  CAS  Google Scholar 

  36. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295(19): 2275–85

    Article  PubMed  CAS  Google Scholar 

  37. Watson K, Symmons D, Griffiths I, et al. The British Society for Rheumatology. Biologics Register. Ann Rheum Dis 2005; 64Suppl. 4: iv42–3

    Article  PubMed  Google Scholar 

  38. Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64(10): 1421–6

    Article  PubMed  CAS  Google Scholar 

  39. Askling J, Baecklund E, Granath F, et al. Anti-TNF therapy in RA and risk of malignant lymphomas: relative risks and time-trend in the Swedish Biologics Register. Ann Rheum Dis 2009; 68(5): 648–53

    Article  PubMed  CAS  Google Scholar 

  40. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007; 56(5): 1433–9

    Article  PubMed  CAS  Google Scholar 

  41. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50(6): 1740–51

    Article  PubMed  CAS  Google Scholar 

  42. Setoguchi S, Schneeweiss S, Avorn J, et al. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J 2008; 156(2): 336–41

    Article  PubMed  CAS  Google Scholar 

  43. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107(25): 3133–40

    Article  PubMed  CAS  Google Scholar 

  44. Listing J, Strangfeld A, Kekow J, et al. Does tumor necrosis factor inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 2008; 58(3): 667–77

    Article  PubMed  CAS  Google Scholar 

  45. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004; 116(5): 305–11

    Article  PubMed  Google Scholar 

  46. Sarzi-Puttini P, Atzeni F, Shoenfeld Y, et al. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun Rev 2005; 4(3): 153–61

    Article  PubMed  CAS  Google Scholar 

  47. Abbas AK, Lichtman AH. Basic immunology. Function and disorders of the immune system. Philadelphia (PA): W.B. Saunders Company, 2001

    Google Scholar 

  48. Fulop T, Larbi A, Dupuis G, et al. Ageing, autoimmunity and arthritis: perturbations of TCR signal transduction pathways with ageing a biochemical paradigm for the ageing immune system. Arthritis Res Ther 2003; 5(6): 290–302

    Article  PubMed  Google Scholar 

  49. Weng NP. Aging of the immune system: how much can the adaptive immune system adapt? Immunity 2006; 24(5): 495–9

    Article  PubMed  CAS  Google Scholar 

  50. Bryl E, Vallejo AN, Weyand CM, et al. Down-regulation of CD28 expression by TNF-alpha. J Immunol 2001; 167(6): 3231–8

    PubMed  CAS  Google Scholar 

  51. Fasth AER, Cao D, van Vollenhoven R, et al. CD28 (null) CD4 (+) T cells: characterization of an effector memory T-cell population in patients with rheumatoid arthritis. Scand J Rheumatol 2004; 60(1–2): 199–208

    CAS  Google Scholar 

  52. Yung RL. Changes in immune function with age. Rheum Dis Clin North Am 2000; 26(3): 455–69

    Article  PubMed  CAS  Google Scholar 

  53. Daynes RA, Araneo BA, Ershler WB, et al. Altered regulation of Il-6 production with normal aging: possible linkage to the age-associated decline in dehydroepiandrosterone and its sulphated derivative. J Immunol 1993; 150(12): 5219–30

    PubMed  CAS  Google Scholar 

  54. Foster KD, Conn CA, Kluger MJ. Fever, tumor-necrosis-factor, and interleukin-6 in young, mature, and aged Fischer 344 rats. Am J Physiol 1992; 262(2): R211–5

    PubMed  CAS  Google Scholar 

  55. Rink L, Cakman I, Kirchner H. Altered cytokine production in the elderly. Mech Ageing Dev 1998; 102(2–3): 199–209

    Article  PubMed  CAS  Google Scholar 

  56. Chung HY, Cesari M, Anton S, et al. Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res Rev 2008; 8(1): 18–30

    Article  PubMed  Google Scholar 

  57. Donato AJ, Black AD, Jablonski KL, et al. Aging is associated with greater nuclear NFkappaB, reduced I-kappa-B-alpha, and increased expression of proinflammatory cytokines in vascular endothelial cells of healthy humans. Aging Cell 2008; 7: 805–12

    Article  PubMed  CAS  Google Scholar 

  58. Mysliwska J, Bryl E, Foerster J, et al. The upregulation of TNF alpha production is not a generalised phenomenon in the elderly between their sixth and seventh decades of life. Mech Ageing Dev 1999; 107(1): 1–14

    Article  PubMed  CAS  Google Scholar 

  59. Cutolo M, Montecucco CM, Cavagna L, et al. Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis. Ann Rheum Dis 2006 Nov; 65(11): 1438–43

    Article  PubMed  CAS  Google Scholar 

  60. Horiuchi T, Yoshida T, Koshihara Y, et al. The increase of parathyroid hormone-related peptide and cytokine levels in synovial fluid of elderly rheumatoid arthritis and os-teoarthritis. Endocr J 1999; 46(5): 643–9

    Article  PubMed  CAS  Google Scholar 

  61. Punzi L, Bertazzolo N, Pianon M, et al. Synovial fluid levels of proinflammatory interleukins and their interrelationships in elderly vs younger onset rheumatoid arthritis. Aging Clin Exp Res 1996; 8(4): 277–81

    CAS  Google Scholar 

  62. Chen DY, Hsieh TY, Chen YM, et al. Proinflammatory cytokine profiles of patients with elderly-onset rheumatoid arthritis: a comparison with younger-onset disease. Gerontology 2008; 55(3): 250–8

    Article  PubMed  Google Scholar 

  63. Fleischmann RM, Baumgartner SW, Tindall EA, et al. Response to etanercept (Enbrel®) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J Rheumatol 2003; 30(4): 691–6

    PubMed  CAS  Google Scholar 

  64. Bathon JM, Fleischmann RM, van der Heijde DM, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol 2006; 33(2): 234–43

    PubMed  CAS  Google Scholar 

  65. Schiff MH, Yu EB, Weinblatt ME, et al. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies. Drugs Aging 2006; 23(2): 167–78

    Article  PubMed  CAS  Google Scholar 

  66. Genevay S, Finckh A, Ciurea A, et al. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007; 57(4): 679–85

    Article  PubMed  Google Scholar 

  67. Radovits BJ, Kievit W, Fransen J, et al. Influence of age on the outcome of anti-TNFα therapy in rheumatoid arthritis. Ann Rheum Dis. Epub 2008 Nov 19

    Google Scholar 

  68. Filippini M, Bazzani C, Zingarelli S, et al. Anti-TNFalpha agents in elderly patients with rheumatoid arthritis: a study of a group of 105 over sixty five years old patients [in Italian]. Reumatismo 2008; 60(1): 41–9

    PubMed  CAS  Google Scholar 

  69. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337(3): 141–7

    Article  PubMed  CAS  Google Scholar 

  70. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130(6): 478–86

    PubMed  CAS  Google Scholar 

  71. Fransen J, van Riel PL. The disease activity score and the EULAR response criteria. Clin Exp Rheumatol 2005; 23 (5 Suppl. 39): S93–9

    PubMed  CAS  Google Scholar 

  72. Fransen J, Langenegger T, Michel BA, et al. Feasibility and validity of the RADAI, a self-administered rheumatoid arthritis disease activity index. Rheumatology (Oxford) 2000; 39(3): 321–7

    Article  CAS  Google Scholar 

  73. Fleischmann R, Baumgartner SW, Weisman MH, et al. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis 2006; 65(3): 379–84

    Article  PubMed  CAS  Google Scholar 

  74. Chevillotte-Maillard H, Ornetti P, Mistrih R, et al. Survival and safety of treatment with infliximab in the elderly population. Rheumatology 2005; 44(5): 695–6

    Article  PubMed  CAS  Google Scholar 

  75. Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Anti-tumor necrosis factor alpha therapy and the risk of severe bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007; 6: 1754–64

    Article  Google Scholar 

  76. Tutuncu Z, Reed G, Kremer J, et al. Do patients with older onset rheumatoid arthritis receive less aggressive treatment than younger patients? Ann Rheum Dis 2006; 65(9): 1226–9

    Article  PubMed  CAS  Google Scholar 

  77. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology 2007; 46(7): 1157–60

    Article  PubMed  CAS  Google Scholar 

  78. Fraenkel L, Rabidou N, Dhar R. Are rheumatologists’ treatment decisions influenced by patients’ age? Rheumatology 2006; 45(12): 1555–7

    Article  PubMed  CAS  Google Scholar 

  79. Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46(9): 2294–300

    Article  PubMed  Google Scholar 

  80. Favalli EG, Desiati F, Atzeni F, et al. Serious infections during anti-TNF treatment in RA patients: clinical practice experience. Autoimmun Rev 2009; 8(3): 266–73

    Article  PubMed  CAS  Google Scholar 

  81. Guralnik JM. Assessing the impact of comorbidity in the older population. Ann Epidemiol 1996; 6(5): 376–80

    Article  PubMed  CAS  Google Scholar 

  82. Jacobsson LTH, Turesson C, Gulfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32(7): 1213–8

    PubMed  CAS  Google Scholar 

  83. Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56(9): 2905–12

    Article  PubMed  CAS  Google Scholar 

  84. Lange U, Teichmann J, Muller-Ladner U, et al. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. Rheumatology (Oxford) 2005; 44(12): 1546–8

    Article  CAS  Google Scholar 

  85. Seriolo B, Paolino S, Sulli A, et al. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Ann N Y Acad Sci 2006; 1069: 420–7

    Article  PubMed  CAS  Google Scholar 

  86. Fraenkel L, Bogardus ST, Concato J, et al. Patient preferences for treatment of rheumatoid arthritis. Ann Rheum Dis 2004; 63(11): 1372–8

    Article  PubMed  CAS  Google Scholar 

  87. Fraenkel L, Bogardus S, Concato J, et al. Risk communication in rheumatoid arthritis. J Rheumatol 2003; 30(3): 443–8

    PubMed  Google Scholar 

  88. Ho M, Lavery B, Pullar T. The risk of treatment: a study of rheumatoid arthritis patients’ attitudes. Br J Rheumatol 1998; 37(4): 459–60

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Rheumatology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, Hp 470, 6500 HB, Nijmegen, the Netherlands

    Beáta J. Radovits, Wietske Kievit & Roland F. J. M. Laan

Authors
  1. Beáta J. Radovits
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wietske Kievit
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roland F. J. M. Laan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Beáta J. Radovits.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Radovits, B.J., Kievit, W. & Laan, R.F.J.M. Tumour Necrosis Factor-α Antagonists in the Management of Rheumatoid Arthritis in the Elderly. Drugs Aging 26, 647–664 (2009). https://doi.org/10.2165/11316460-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11316460-000000000-00000

Keywords

Search

Navigation